View More View Less
  • 1 Hungarian Defence Forces Dr György Radó Military Medical Center, Budapest, Hungary
  • 2 Military Hospital-State Health Centre, Scientific Institute, P.O. Box 1, H-1553, Budapest, Hungary
  • 3 H-1118, Budapest, Rétköz utca 47/C, 2/2, Hungary
Restricted access

Summary

A sensitive method was developed for the determination of free morphine and codeine in blood. This method is suitable for detection of the ingestion of illicit drugs. This test is applicable for monitoring therapeutic doses as well as stand up in the court of law. For the test we use with deuterium tagged morphine and codeine. We tag the blood specimens with deuterium prior to testing. The active ingredients (morphine and codeine) are extracted by solid phase extraction, and eventually derivatized with pentafluoro propionic anhydride (PFPA). The resulting compounds are stable and have good chromatographic characteristics. The Gas-chromatograph coupled Mass-spectrometer (GC/MS) system is used to determine the concentration of the resulting compounds using or/in the selective ion mode (SIM). The results of the target and qualifier ions were 414, 577, 361 in the case of morphine, and 282, 445 in the case of codeine. During our measurements, the graph was linear between 1 and 100 ng / mL. All the results of the qualifications were in line with the German Standards DIN 32645, which were checked with the B.E.N. program.

  • [1]. Fed. Regist. 59, 29922 (1994).

  • [2]. J.H. Autry III 1990 Notice to all DHHS/NIDA Certified Laboratories United States of America Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration Rockville, MD.

    • Search Google Scholar
    • Export Citation
  • [3]. M. Mátyus Gy. Kocsis J. Fűrész 2005 Honvédorvos 57 172180.

  • [4]. M. Thevis G. Opfermann W. Schaenzer 2003 J. Anal. Toxicol. 27 5358.

  • [5]. R. Meatherall 2005 J. Anal. Toxicol. 29 301308.

  • [6]. M. Herbold and G. Schmitt, B.E.N. Program, Institut für Rechts- und Verkehrsmedizin, Heidelberg, 1999.

  • [7]. J.D. Ropero-Miller M.K. Lambing R.E. Winecker 2002 J. Anal. Toxicol. 26 524528.

  • [8]. K. Róna K. Ary L. Vereczkey 1997 Acta Pharm. Hung. 67 51.

  • [9]. J. Trafkowski B. Madea F. Musshoff 2006 Ther. Drug Monit. 28 552558.

  • [10]. B.A. Rashid G.W. Aherne M.F. Katmeh P. Kwasowski D. Stevenson 1998 J. Chromatogr. A 797 245250.

  • [11]. T. Hyötylainen H. Keski-Hynnila M.-L. Riekkola 1997 J. Chromatogr. A 771 360365.

  • [12]. O.H. Drummer 2006 Clin. Biochem. Rev. 27 147159.

  • [13]. L. Tsanaclis J.F. Wicks 2007 Forensic Sci. Int. 170 121128.

  • [14]. T. Kramer L.D. Paul 2007 Anal. Bioanal. Chem. 388 14151435.

  • [15]. R. Coles M.M. Kushnir G.J. Nelson G.A. McMillin F.M. Urry 2007 J. Anal. Toxicol. 31 114.

  • [16]. L. Bachs G. Hoiseth S. Skurtveit J. Morland 2006 Eur. J. Clin. Pharmacol. 62 905912.

  • [17]. Deutsches Institut für Normung 32645, Nachweis-, Erfassung- und Bestimmungsgrenze, Beuth Verlag, Berlin, 1994.

  • [18]. M. Herbold G. Schmitt 1998 Toxichem. Krimtech. 65 8796.

  • [19]. G. Schmitt M. Herbold F. Peters 2003 Methodenvalidierung im forensisch-toxikologischen Labor Arvecon GmbH Heidelberg.

  • [20]. M.J. Bogusz K.D. Krüger R.D. Maier 2000 J. Anal. Toxicol. 24 7787.

  • [21]. H.H. Maurer 2002 Ther. Drug Monit. 24 247254.

  • [22]. M.R. Moeller T. Kraemer 2002 Ther. Drug Monit 24 210221.

  • [23]. F. Bressole M. Bromet-Petit M. Audram 1996 J. Chromatogr. B 686 310.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2020 7 0 0
Dec 2020 1 0 0
Jan 2021 3 0 0
Feb 2021 2 0 0
Mar 2021 4 0 0
Apr 2021 1 0 0
May 2021 0 0 0